In the U.S., More People Are Dying from Myasthenia Gravis —That’s the main take-away from a new study, which investigated mortality trends among patients with myasthenia gravis from 1999 to 2022.

Myasthenia gravis affects both men and women and occurs across all races and ethnicities. Its incidence and prevalence are higher in women under age 50 and in men ages 65 and older.

Cartesian Therapeutics enrolls first participant in Phase 3 trial of Descartes-08 for myasthenia gravis treatment.

Aside from Myasthenia Gravis, Telitacicept has been approved in China for the treatment of two other major indications, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Tanruprubart demonstrates superior muscle recovery and quality of life improvement in Guillain-Barré Syndrome patients over standard treatments.

Sufjan Stevens gave a rare health update following his 2023 diagnosis with Guillain-Barré syndrome "I’m okay. Situation normal, all up, kind of a thing," Stevens said in an interview with ...

Johnson & Johnson’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The drug will be marketed under the brand name Imaavy. With the approval, J&J is ...

FDA Approves Johnson & Johnson’s IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis.

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific kinase ...

"Generalized myasthenia gravis can cause you to miss out on a zillion things," begins the commercial's female voiceover.

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the treatment of generalized myasthenia gravis.